Automated drug screening with contractile muscle tissue engineered from dystrophic myoblasts

FASEB Journal

Volumn 23, Issue 10, 2009, Pages 3325-3334

  Vandenburgh, Herman ^a,c   Shansky, Janet ^a,c   Benesch Lee, Frank ^c   Skelly, Kirsten ^c   Spinazzola, Janelle M ^c   Saponjian, Yero ^b   Tseng, Brian S ^b  

^a BROWN UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Myomics Inc   (United States)

Author keywords

Cardiovascular drugs; Dietary supplements; Glucocorticoids; mdx mouse; Tetanic force

Indexed keywords

ARGININE; BETA HYDROXY BETA METHYLBUTYRATE; CREATINE; DEFLAZACORT; HYDROXYACID; LISINOPRIL; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISONE; SOMATOMEDIN C; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; AUTOMATION; CHEMICAL INTERACTION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG SCREENING; DUCHENNE MUSCULAR DYSTROPHY; ELECTROSTIMULATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MUSCLE CELL; MUSCLE CONTRACTILITY; MUSCLE DISEASE; MUSCLE FUNCTION; MUSCLE STRENGTH; MUSCLE TETANIC CONTRACTION; MUSCLE TISSUE; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; PRIORITY JOURNAL; TISSUE ENGINEERING;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ELECTRIC STIMULATION; MALE; MICE; MICE, INBRED MDX; MUSCLE CONTRACTION; MUSCULAR DYSTROPHY, DUCHENNE; MYOBLASTS; TISSUE ENGINEERING;

MURINAE;

EID: 70349666554     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.09-134411     Document Type: Article

References (55)

1. Vandenburgh, H. H., Swasdison, S., and Karlisch, P. (1991) Computer aided mechanogenesis of skeletal muscle organs from single cells in vitro. FASEB J. 5, 2860-2867 (Pubitemid 21892859)
2. Langer, R., and Vacanti, J. P. (1993) Tissue engineering. Science 260, 920-926
3. Khademhosseini, A., Langer, R., Borenstein, J., and Vacanti, J. P. (2006) Microscale technologies for tissue engineering and biology. Proc. Natl. Acad. Sci. U. S. A. 103, 2480-2487 (Pubitemid 43306575)
4. Terstappen, G. C., Schlupen, C., Raggiaschi, R., and Gaviraghi, G. (2007) Target deconvolution strategies in drug discovery. Nat. Rev. Drug Discov. 6, 891-903 (Pubitemid 350042397)
5. Gaud, A., Simon, J. M., Witzel, T., Carre-Pierrat, M., Wermuth, C. G., and Segalat, L. (2004) Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul. Disord. 14, 365-370
6. Catoire, H., Pasco, M. Y., Abu-Baker, A., Holbert, S., Tourette, C., Brais, B., Rouleau, G. A., Parker, J. A., and Neri, C. (2008) Sirtuin inhibition protects from the polyalanine muscular dystrophy protein PABPN1. Human Mol. Genetics 17, 2108-2117 (Pubitemid 351911980)
7. Steffen, L. S., Guyon, J. R., Vogel, E. D., Beltre, R., Pusack, T. J., Zhou, Y., Zon, L. I., and Kunkel, L. M. (2007) Zebrafish orthologs of human muscular dystrophy genes. BMC Genomics 8, 79 (Pubitemid 46566603)
8. Vandenburgh, H., Shansky, J., Benesch-Lee, F., Barbata, V., Reid, J., Thorrez, L., Valentini, R., and Crawford, G. (2008) A drug screening platform based on the contractility of tissue engineered muscle. Muscle Nerve 37, 438-447
9. Matsumura, K., and Campbell, K. P. (1994) Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Muscle Nerve 17, 2-15 (Pubitemid 24012098)
10. Khurana, T. S., and Davies, K. E. (2003) Pharmacological strategies for muscular dystrophy. Nat. Rev. Drug Discov. 2, 379-390
11. Tidball, J. G., and Wehling-Henricks, M. (2004) Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. Pediatr. Res. 56, 831-841
12. Morgan, J. E., Beauchamp, J. R., Pagel, C. N., Peckham, M., Ataliotis, P., Jat, P. S., Noble, M. D., Farmer, K., and Partridge, T. A. (1994) Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev. Biol. 162, 486-498 (Pubitemid 24144125)
13. Payne, E. T., Yasuda, N., Bourgeois, J. M., Devries, M. C., Rodriguez, M. C., Yousuf, J., and Tarnopolsky, M. A. (2006) Nutritional therapy improves function and complements corticosteroid intervention in mdx mice. Muscle Nerve 33, 66-77 (Pubitemid 43062988)
14. Granchelli, J. A., Pollina, C., and Hudecki, M. S. (2000) Preclinical screening of drugs using the mdx mouse. Neuromusc. Disord. 10, 235-239 (Pubitemid 30320912)
15. Minetti, G. C., Colussi, C., Adami, R., Serra, C., Mozzetta, C., Parente, V., Fortuni, S., Straino, S., Sampaolesi, M., Di Padova, M., Illi, B., Gallinari, P., Steinkuhler, C., Capogrossi, M. C., Sartorelli, V., Bottinelli, R., Gaetano, C., and Puri, P. L. (2006) Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat. Med. 12, 1147-1150 (Pubitemid 44527349)
16. Schertzer, J. D., Ryall, J. G., and Lynch, G. S. (2006) Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Am. J. Physiol. Endocrinol. Metab. 291, E499-E505
17. Cohn, R. D., van Erp, C., Habashi, J. P., Soleimani, A. A., Klein, E. C., Lisi, M. T., Gamradt, M., Ap Rhys, C. M., Holm, T. M., Loeys, B. L., Ramirez, F., Judge, D. P., Ward, C. W., and Dietz, H. C. (2007) Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210 (Pubitemid 46245764)
18. Ciafaloni, E., and Moxley, R. T. (2008) Treatment options for Duchenne muscular dystrophy. Curr. Treat. Options Neurol. 10, 86-93
19. Steen, M. S., Adams, M. E., Tesch, Y., and Froehner, S. C. (2009) Amelioration of muscular dystrophy by transgenic expression of Niemann-Pick C1. Mol. Biol. Cell 20, 146-152
20. Archer, J. D., Vargas, C. C., and Anderson, J. E. (2006) Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort. FASEB J. 20, 738-740
21. Escolar, D. M., Gorni, K., Tesi-Rocha, A. C., Mah, J., Nevo, Y., Korengberg, A., Kolski, H., Bertorini, T., Connolly, A., Kuntz, N., Zimmerman, A., Morgenroth, L., Arrieta, A., Mayhew, J., Florence, J., Nei, L., Hu, F., Henricson, E., Leshner, R., and Dubrovsky, A. (2008) Pentoxifylline treatment fails to rescue muscle strength and function deterioration in prednisonetreated Duchenne muscular dystrophy (DMD). Neuromuscul. Disord. 18, 824
22. Yeung, E. W., Head, S. I., and Allen, D. G. (2003) Gadolinium reduces short-term stretch-induced muscle damage in isolated mdx mouse muscle fibres. J. Physiol. 552, 449-458
23. Franco-Obregon, A., and Lansman, J. B. (2002) Changes in mechanosensitive channel gating following mechanical stimulation in skeletal muscle myotubes from the mdx mouse. J. Physiol. 539, 391-407 (Pubitemid 35175396)
24. Moens, P., Baatsen, P. H., and Marechal, G. (1993) Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J. Muscle Res. Cell Motil. 14, 446-451 (Pubitemid 23267492)
25. Sampaolesi, M., Yoshida, T., Iwata, Y., Hanada, H., and Shigekawa, M. (2001) Stretch-induced cell damage in sarcoglycan- deficient myotubes. Pflügers Arch. 442, 161-170 (Pubitemid 32476632)
26. Petrof, B. J., Shrager, J. B., Stedman, H. H., Kelly, A. M., and Sweeney, H. L. (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U. S. A. 90, 3710-3714 (Pubitemid 23111437)
27. Kumar, A., Khandelwal, N., Malya, R., Reid, M. B., and Boriek, A. M. (2004) Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. FASEB J. 18, 102-113 (Pubitemid 38076470)
28. Acharyya, S., Butchbach, M. E., Sahenk, Z., Wang, H., Saji, M., Carathers, M., Ringel, M. D., Skipworth, R. J., Fearon, K. C., Hollingsworth, M. A., Muscarella, P., Burghes, A. H., Rafael- Fortney, J. A., and Guttridge, D. C. (2005) Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia. Cancer Cell 8, 421-432 (Pubitemid 41579836)
29. Tarnopolsky, M. A., Mahoney, D. J., Vajsar, J., Rodriguez, C., Doherty, T. J., Roy, B. D., and Biggar, D. (2004) Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62, 1771-1777 (Pubitemid 38661733)
30. Hudecki, M. S., Pollina, C. M., Granchelli, J. A., Daly, M. K., Byrnes, T., Wang, J. C., and Hsiao, J. C. (1993) Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice. Res. Commun. Chem. Pathol. Pharmacol. 79, 45-60 (Pubitemid 23039209)
31. Nissen, S. L., and Sharp, R. L. (2003) Effect of dietary supplements on lean mass and strength gains with resistance exercise: a meta-analysis. J. Appl. Physiol. 94, 651-659
32. McNally, E. M. (2008) Duchenne muscular dystrophy: how bad is the heart? Heart 94, 976-977 (Pubitemid 352039876)
33. Sumukadas, D., Struthers, A. D., and McMurdo, M. E. (2006) Sarcopenia-a potential target for angiotensin-converting enzyme inhibition? Gerontology 52, 237-242 (Pubitemid 44114443)
34. Bonifati, M. D., Ruzza, G., Bonometto, P., Berardinelli, A., Gorni, K., Orcesi, S., Lanzi, G., and Angelini, C. (2000) A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve 23, 1344-1347 (Pubitemid 30690987)
35. Chromiak, J. A., and Vandenburgh, H. H. (1992) Glucocorticoidinduced skeletal muscle atrophy in vitro is attenuated by mechanical stimulation. Am. J. Physiol. Cell Physiol. 262, C1471-C1477
36. Clarke, B. A., Drujan, D., Willis, M. S., Murphy, L. O., Corpina, R. A., Burova, E., Rakhilin, S. V., Stitt, T. N., Patterson, C., Latres, E., and Glass, D. J. (2007) The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6, 376-385 (Pubitemid 350011998)
37. Golumbek, P. T., Keeling, R. M., and Connolly, A. M. (2007) Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromusc. Disord. 17, 376-384
38. Leijendekker, W. J., Passaquin, A.-C., Metzinger, L., and Ruegg, U. T. (1996) Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress. Br. J. Pharmacol. 118, 611-616 (Pubitemid 26180974)
39. Courdier-Fruh, I., Barman, L., Briguet, A., and Meier, T. (2002) Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers. Neuromuscul. Disord. 12(Suppl. 1), S95-S104 (Pubitemid 36158779)
40. 2+ channels by dystrophin, the actin cytoskeleton, and cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. U. S. A. 102, 4191-4196
41. Metzinger, L., Passaquin, A. C., Leijendekker, W. J., Poindron, P., and Ruegg, U. T. (1995) Modulation by prednisolone of calcium handling in skeletal muscle cells. Br. J. Pharmacol. 116, 2811-2816
42. Fisher, I., Abraham, D., Bouri, K., Hoffman, E. P., Muntoni, F., and Morgan, J. (2005) Prednisolone-induced changes in dystrophic skeletal muscle. FASEB J. 19, 834-836 (Pubitemid 40617400)
43. Passaquin, A.-C., Renard, M., Kay, L., Challet, C., Mokhtarian, A., Wallimann, T., and Ruegg, U. T. (2002) Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromusc. Disord. 12, 174-182 (Pubitemid 33152736)
44. McClure, W. C., Rabon, R. E., Ogawa, H., and Tseng, B. S. (2007) Upregulation of the creatine synthetic pathway in skeletal muscles of mature mdx mice. Neuromuscul. Disord. 17, 639-650 (Pubitemid 47033926)
45. Bellinger, A. M., Mongillo, M., and Marks, A. R. (2008) Stressed out: the skeletal muscle ryanodine receptor as a target of stress. J. Clin. Invest. 118, 445-453 (Pubitemid 351206532)
46. Chamberlain, J. S., and Rando, T. A. (2006) Duchenne Muscular Dystrophy: Advances in Therapeutics, Informa HealthCare, New York
47. Grounds, M. D. (2008) Two-tiered hypotheses for Duchenne muscular dystrophy. Cell. Mol. Life Sci. 65, 1621-1625
48. Siegel, A. L., Bledsoe, C., Lavin, J., Gatti, F., Berge, J., Millman, G., Turin, E., Winders, W. T., Rutter, J., Palmeiri, B., and Carlson, C. G. (2008) Treatment with inhibitors of the NFkappaB pathway improves whole body tension development in the mdx mouse. Neuromuscul. Disord. 19, 131-139
49. Asai, A., Sahani, N., Kaneki, M., Ouchi, Y., Martyn, J. A., and Yasuhara, S. E. (2007) Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase- 5 inhibitor therapy in mouse muscular dystrophy. PLoS ONE 2, e806
50. Brunelli, S., Sciorati, C., D'Antona, G., Innocenzi, A., Covarello, D., Galvez, B. G., Perrotta, C., Monopoli, A., Sanvito, F., Bottinelli, R., Ongini, E., Cossu, G., and Clementi, E. (2007) Nitric oxide release combined with nonsteroidal anti-inflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy. Proc. Natl. Acad. Sci. U. S. A. 104, 264-269 (Pubitemid 46068020)
51. Villalta, S. A., Nguyen, H. X., Deng, B., Gotoh, T., and Tidball, J. G. (2009) Shifts in macrophage phenotypes and macrophage competition for arginine metabolism affect the severity of muscle pathology in muscular dystrophy. Hum. Mol. Genet. 18, 482-496
52. Ng, R., Metzger, J. M., Claflin, D. R., and Faulkner, J. A. (2008) Poloxamer 188 reduces the contraction-induced force decline in lumbrical muscles from mdx mice. Am. J. Physiol. Cell Physiol. 295, C146-C150 (Pubitemid 352755798)
53. Zhu, C. H., Mouly, V., Cooper, R. N., Mamchaoui, K., Bigot, A., Shay, J. W., Di Santo, J. P., Butler-Browne, G. S., and Wright, W. E. (2007) Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclindependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 6, 515-523 (Pubitemid 47087056)
54. Tanaka, M., Bateman, R., Rauh, D., Vaisberg, E., Ramachandani, S., Zhang, C., Hansen, K. C., Burlingame, A. L., Trautman, J. K., Shokat, K. M., and Adams, C. L. (2005) An unbiased cell morphology based screen for new, biologically active small molecules. PLoS Biol. 3, e128 (Pubitemid 40958400)
55. Welch, E. M., Barton, E. R., Zhuo, J., Tomizawa, Y., Friesen, W. J., Trifillis, P., Paushkin, S., Patel, M., Trotta, C. R., Hwang, S., Wilde, R. G., Karp, G., Takasugi, J., Chen, G., Jones, S., Ren, H., Moon, Y. C., Corson, D., Turpoff, A. A., Campbell, J. A., Conn, M. M., Khan, A., Almstead, N. G., Hedrick, J., Mollin, A., Risher, N., Weetall, M., Yeh, S., Branstrom, A. A., Colacino, J. M., Babiak, J., Ju, W. D., Hirawat, S., Northcutt, V. J., Miller, L. L., Spatrick, P., He, F., Kawana, M., Feng, H., Jacobson, A., Peltz, S. W., and Sweeney, H. L. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447, 87-91 (Pubitemid 46685839)